Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia.

Authors :: Zhang T
Zhou H
Xu M
Qian C
Sun A
Wu D
Xue S
Source :: Annals of hematology [Ann Hematol] 2023 Apr; Vol. 102 (4), pp. 973-975. Date of Electronic Publication: 2023 Feb 06.
Publication Year :: 2023

Subjects :: Humans
Blast Crisis drug therapy
Bridged Bicyclo Compounds, Heterocyclic therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Leukemia, Myeloid drug therapy
Leukemia, Myeloid, Acute drug therapy

Full Text Access

Tools